AU2019449809B2 - Crystalline salt forms of a kinase inhibitor - Google Patents

Crystalline salt forms of a kinase inhibitor

Info

Publication number
AU2019449809B2
AU2019449809B2 AU2019449809A AU2019449809A AU2019449809B2 AU 2019449809 B2 AU2019449809 B2 AU 2019449809B2 AU 2019449809 A AU2019449809 A AU 2019449809A AU 2019449809 A AU2019449809 A AU 2019449809A AU 2019449809 B2 AU2019449809 B2 AU 2019449809B2
Authority
AU
Australia
Prior art keywords
compound
degrees
xrpd pattern
following peaks
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019449809A
Other languages
English (en)
Other versions
AU2019449809A1 (en
Inventor
Melanie Janelle Bevill
Frenel Demorin
Courtney S. Johnson
Stephan D. Parent
Khalid Shah
Sagar Shakya
Peter Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2019449809A1 publication Critical patent/AU2019449809A1/en
Application granted granted Critical
Publication of AU2019449809B2 publication Critical patent/AU2019449809B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019449809A 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor Active AU2019449809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
US62/856,404 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (2)

Publication Number Publication Date
AU2019449809A1 AU2019449809A1 (en) 2021-12-16
AU2019449809B2 true AU2019449809B2 (en) 2026-02-05

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019449809A Active AU2019449809B2 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Country Status (22)

Country Link
US (1) US20230052703A1 (enExample)
EP (1) EP3976587B1 (enExample)
JP (1) JP7579281B2 (enExample)
KR (1) KR102826380B1 (enExample)
CN (1) CN113939503B (enExample)
AU (1) AU2019449809B2 (enExample)
BR (1) BR112021024300A2 (enExample)
CA (1) CA3139148A1 (enExample)
CL (1) CL2021003205A1 (enExample)
CO (1) CO2021017343A2 (enExample)
CR (1) CR20210616A (enExample)
DO (1) DOP2021000236A (enExample)
ES (1) ES3008963T3 (enExample)
GE (2) GEP20247655B (enExample)
IL (1) IL288484A (enExample)
MA (1) MA56001A (enExample)
MX (1) MX2021014773A (enExample)
PE (1) PE20220962A1 (enExample)
PH (1) PH12021553020A1 (enExample)
SG (1) SG11202111978VA (enExample)
WO (1) WO2020247019A1 (enExample)
ZA (1) ZA202108034B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
US20250368606A1 (en) 2021-12-22 2025-12-04 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
WO2018218233A1 (en) * 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN109761899A (zh) * 2019-02-14 2019-05-17 陆瑞燕 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
WO2019148044A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
ES2598530T3 (es) * 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
WO2018218233A1 (en) * 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2019148044A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN109761899A (zh) * 2019-02-14 2019-05-17 陆瑞燕 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
PH12021553020A1 (en) 2023-08-23
JP7579281B2 (ja) 2024-11-07
ES3008963T3 (en) 2025-03-25
EP3976587A1 (en) 2022-04-06
EP3976587B1 (en) 2024-12-04
BR112021024300A2 (pt) 2022-01-11
SG11202111978VA (en) 2021-11-29
CN113939503A (zh) 2022-01-14
CN113939503B (zh) 2024-05-07
IL288484A (en) 2022-01-01
KR102826380B1 (ko) 2025-06-26
AU2019449809A1 (en) 2021-12-16
DOP2021000236A (es) 2022-04-18
CA3139148A1 (en) 2020-12-10
GEAP202415849A (en) 2024-03-11
KR20220016117A (ko) 2022-02-08
PE20220962A1 (es) 2022-06-10
US20230052703A1 (en) 2023-02-16
EP3976587C0 (en) 2024-12-04
JP2022535072A (ja) 2022-08-04
MA56001A (fr) 2022-04-06
WO2020247019A1 (en) 2020-12-10
CO2021017343A2 (es) 2022-01-17
GEP20247655B (en) 2024-08-26
ZA202108034B (en) 2025-02-26
CR20210616A (es) 2022-03-22
CL2021003205A1 (es) 2022-09-30
MX2021014773A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
US20240300897A1 (en) Crystalline forms and salt forms of a kinase inhibitor
AU2019449809B2 (en) Crystalline salt forms of a kinase inhibitor
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
OA20944A (en) Crystalline salt forms of a kinase inhibitor
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы
HK40067664B (zh) 激酶抑制剂的结晶盐形式
BR122025022768A2 (pt) Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados
EA044424B1 (ru) Кристаллические формы и солевые формы ингибитора киназы